On August 11, Veeva Systems Inc. (NYSE:VEEV) announced that Eli Lilly and Company (NYSE:LLY) committed to deploying Veeva Vault CRM globally. Vault CRM serves as the core infrastructure for "agentic commercial," Veeva's AI-driven commercial framework designed to modernize field engagement and speed medicine delivery. While Veeva serves as the tech engine driving efficiency in life sciences, Eli Lilly stands as the pharmaceutical titan creating those therapies.
Both occupy distinct sectors, enterprise software versus biopharmaceuticals, yet their expanding partnership highlights how technology and drug development are becoming deeply intertwined. Since Veeva Systems Inc. (NYSE:VEEV) is a vertical SaaS vendor and Eli Lilly and Company (NYSE:LLY) is a pharmaceutical manufacturer, direct financial comparison must account for their unique models. Enterprise tech relies on recurring subscriptions and high operating leverage, whereas biopharma depends on clinical trial velocity, manufacturing scale, and global regulatory approvals.
In its Fiscal 2027 First Quarter (ended April 30, 2026), Veeva delivered total revenue of $882.9 million, up 16% year-over-year, driven by $730.2 million in subscription revenue (up 15%). Non-GAAP EBIT reached $395 million, yielding an impressive operating margin above 44%. Eli Lilly demonstrated remarkable top-line acceleration in Q2 2026.
Revenue surged 48% year-over-year to $22.97 billion, propelled by explosive volume demand for GLP-1 therapies Mounjaro and Zepbound. Non-GAAP net income rose 32% to $7.49 billion ($8.38 per share). Lilly raised its full-year 2026 revenue guidance to $85.0–$87.0 billion, underscoring its operational momentum despite absorbing $3.03 per share in acquired R&D charges.
On August 7, Truist raised its price target on LLY to $1,376 from $1,370 with a Buy rating, citing substantial incretin volume growth offsetting pricing pressure. LLY's momentum extends well beyond commercial execution into regulatory breakthroughs. On August 10, the UK's MHRA authorized Foundayo (orforglipron), making Britain the first European country to approve Lilly's once-daily oral GLP-1 pill for weight management and type 2 diabetes.
Unlike existing oral options, Foundayo carries no food or water restrictions, positioning it as a major catalyst to expand treatment access globally. The latest Insider Monkey hedge fund tracking data points to a modest decline in institutional participation across both equities in Q1 2026. Veeva Systems Inc. (NYSE:VEEV) was held by 62 hedge funds, down from 75 in Q4 2025.
Extract — continue reading at the source.
